Payment overview · 2025
General Payments
$69.78
3 reported records · 3 companies
Healthcare provider profile · identity verified
Dean W. Singer, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GREENFIELD, MA · NPI 1396131538
Verified facts
What the public records show
CMS Open Payments records show Dean W. Singer, D.O. received $69.78 in general payments during 2025 across 3 reported records.
Indivior Inc. accounted for 47.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Sublocade.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Indivior Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SUBLOCADE as an associated drug or biological on 22829 records involving 8874 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Sublocade by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $33.32 | 47.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.46 | 27.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.00 | 24.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $69.78 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $33.32 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 196 | exact normalized | Medicare Part D |
| SUBLOCADE sublocade |
2025 | Sublocade | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
196 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Indivior Inc. Exact reporting entity; no affiliate inference |
2025 | SUBLOCADE open payments reported associated product |
CMS Open Payments — General Payments 22829 supporting records · 8874 recipient NPIs · example record 1240470773 |
Sublocade · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 416 | 97 |
| Gabapentin | Gabapentin | 310 | 57 |
| Oxycodone Hcl | Oxycodone Hcl | 291 | 42 |
| Omeprazole | Omeprazole | 263 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 256 | 58 |
| Lisinopril | Lisinopril | 240 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 53 |
| Eliquis | Apixaban | 196 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 190 | 39 |
| Lorazepam | Lorazepam | 185 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 42 |
| Trazodone Hcl | Trazodone Hcl | 160 | 32 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 151 | 17 |
| Clonazepam | Clonazepam | 139 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 41 |
| Furosemide | Furosemide | 136 | 29 |
| Losartan Potassium | Losartan Potassium | 135 | 38 |
| Methadone Hcl | Methadone Hcl | 131 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 36 |
| Sertraline Hcl | Sertraline Hcl | 120 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 29 |
| Jardiance | Empagliflozin | 111 | 21 |
| Simvastatin | Simvastatin | 111 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 108 | 18 |
| Metformin Hcl | Metformin Hcl | 107 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 22 |
| Prednisone | Prednisone | 86 | 50 |
| Clonidine Hcl | Clonidine Hcl | 85 | 15 |
| Spironolactone | Spironolactone | 85 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 22 |
| Bupropion Xl | Bupropion Hcl | 77 | 19 |
| Allopurinol | Allopurinol | 76 | 21 |
| Alprazolam | Alprazolam | 75 | suppressed |
| Chlorthalidone | Chlorthalidone | 73 | 18 |
| Mirtazapine | Mirtazapine | 72 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | suppressed |
| Trulicity | Dulaglutide | 69 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 13 |
| Ozempic | Semaglutide | 65 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 63 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 48 |
| Ondansetron Odt | Ondansetron | 58 | 24 |
| Farxiga | Dapagliflozin Propanediol | 57 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 17 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Diazepam | Diazepam | 54 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 53 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 14 |
| Fentanyl | Fentanyl | 50 | suppressed |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Famotidine | Famotidine | 48 | 16 |
| Valacyclovir | Valacyclovir Hcl | 48 | 20 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Ibuprofen | Ibuprofen | 47 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Celecoxib | Celecoxib | 43 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | 13 |
| Wegovy | Semaglutide | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 37 | suppressed |
| Meloxicam | Meloxicam | 37 | 13 |
| Primidone | Primidone | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 33 |
| Carvedilol | Carvedilol | 36 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 29 |
| Hydromorphone Hcl | Hydromorphone Hcl | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 11 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Loperamide | Loperamide Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Oxycontin | Oxycodone Hcl | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Valsartan | Valsartan | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Sublocade | Buprenorphine | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Qulipta | Atogepant | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Tacrolimus | Tacrolimus | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Zonisamide | Zonisamide | 16 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Baclofen | Baclofen | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Risperidone Er | Risperidone Microspheres | 12 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Methylphenidate Hcl Er (Cd) | Methylphenidate Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $69.78 · 3 records | Indivior Inc. | AREXVY, BEXSERO, ELIQUIS, SUBLOCADE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error